SCN LEAVES OSLO AXESS

As previously communicated, SCN has applied for de-listing of the company’s shares from the Norwegian Oslo Axess list. On August 17, 2009, Oslo Börs decided to approve the application. The last trading day for the SCN share on Oslo Axess will be September 17, 2009. The listing on NGM Equity remains unchanged.

As previously communicated, an extraordinary general meeting in Scandinavian Clinical Nutrition AB (SCN) held on May 20, 2009, decided to apply for de-listing of the company’s shares from Oslo Axess. Oslo Börs has now decided to approve the application and de-list the company’s shares. The last day of trade on Oslo Axess will be September 17, 2009.

The listing on the Swedish NGM Equity list remains unchanged. Known Norwegian shareholders will be contacted shortly with information about how to trade on NGM Equity.

For more information, please contact:

Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81

Jörn Erik Aas, Chairman of the Board, jea@scnutrition.com, +47 924 99 360

Scandinavian Clinical Nutrition i Sverige AB (publ)) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as thin400, CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).For more information, please visit www.scnutrition.com.